Your device is not supported to view the app, please use landscape view or screen 320px or more.

 
 
 

News

North West Coast GMC nominated for an HSJ Award

Congratulations to the NWC GMC on being nominated for a Health Service Journal (HSJ) Award in the category ‘Improving Outcomes Through Learning andDevelopment’ for “Bringing Genomics...

READ MORE
 

Liverpool Shine Walk

Our wonderful NWC GMC Lab staff are extending their care to Cancer Research UK by walking in the Liverpool Shine Walk 10K on 8th September. You can support them by sponsoring & retweeting for this...

READ MORE
 
 

Events

Coming soon
 

 

Our Work

The below list shows the disorders which the NWC GMC are currently recruiting for. Further disorders will be approved following nomination by clinicians and researchers.

Cancer

  • Breast

  • Colon

  • Lung

  • Ovarian

  • Prostate

Rare

  • Cardiovascular disorders

  • Dermatological disorders

  • Dysmorphic and congenital abnormality syndromes

  • Endocrine disorders

  • Growth disorders

  • Haematological disorders

  • Hearing and ear disorders

  • Metabolic disorders

  • Neurology and neurodevelopmental disorders

  • Ophthalmological disorders

  • Renal and urinary tract disorders

  • Skeletal, rheumatological, and connective tissue disorders

  • Tumour predisposition syndromes


Clinicians working for the NWC GMC will invite patients under the care of the NHS to join the project, because they have either a (suspected) rare inherited disorder, or certain forms of (suspected) cancer.  You can also apply directly by contacting us here.

The goals of the Cancer recruitment programme as outlined in the Genomics England Protocol are:

  • To use whole genome sequencing to identify novel driver mutations for cancer and to understand the evolutionary genetic architecture of cancer through primary and secondary malignant disease (by multiple biopsy and WGS);

  • To partner stratified healthcare programmes with participants from the NHS in England to enable understanding of the benefit of WGS in defining predictors of therapeutic response to cancer therapies;

  • To use multi-omic approaches including transcriptomics, proteomics and epigenetics to offer additional biological insights into cancer;

  • To utilise the whole genome sequencing to identify new pathways for cancer therapies.

The goals of the Rare Disease Programme as outlined in the Genomics England Protocol are:

  • To increase discovery of pathogenic variants for rare disease;

  • To add value with additional biological insights that build confidence in putative pathogenic variants;

  • To enhance the clinical interpretation of Whole Genome Sequencing ("WGS") in rare disease;

  • To develop functional multi-omics pathways, specifically transcriptomics, epigenetics, micro RNAs and biomarkers;

  • To return these findings to the NHS for feedback to participants;

  • To create a unique dataset for rare disease that may enable therapeutic innovation.